Following representations from Community Pharmacy England, the Department of Health of Social Care (DHSC) has re-determined the special container status of Drospirenone (Slynd®) 4mg tablets. From 1 June 2024, Drospirenone (Slynd®) 4mg tablets were re-classified as a special container at sub-pack level (sub-pack of 28) as they meet the relevant criteria as set out in Part II
Read moreClass 4 Medicines Defect Information: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.) Drug alert number: EL (24)A/18 Date issued: 03 June 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Betamethasone Valerate 0.1% Ointment (Manx Healthcare Ltd.) Company name: Manx Healthcare Ltd. Product name: Betamethasone Valerate
Read moreCommunity pharmacy owners are being asked to share information on the pressures on their businesses, as well as their key messages for the new Government, ahead of the next full Community Pharmacy England Committee meeting at the end of June. A key focus of this committee meeting will be the General Election campaign and plans
Read moreA recent report published by Healthwatch England highlights that the cost of living pressures are affecting people’s ability to afford prescription and over-the-counter medicines. Freedom of Information data from 2021, found that over a million people could have saved money through NHS prescription prepayment certificates (PPCs). Therefore, Healthwatch England is calling for improvements to NHS
Read moreCommunity Pharmacy England’s Pharmacy Advice Audit is taking place over the next fortnight (3rd to 16th June 2024), and we would be hugely grateful to anyone who is able to take part. Pharmacy owners and their teams are encouraged to record information about the informal healthcare advice that they are giving over the course of
Read moreCommunity pharmacies are being asked for your help to measure the unfunded care the public receives from you. We need pharmacy owners and your teams to take part in our Pharmacy Advice Audit between 3rd to 16th June 2024. The evidence gathered will be critical in supporting Community Pharmacy England’s ongoing case for more funding, particularly
Read moreBefore Parliament was dissolved, the government introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones. This follows the Cass Review into gender identity services. New restrictions on puberty blockers – GOV.UK (www.gov.uk) Today the General Pharmaceutical Council (GPhC) has cascaded NHS England information on the new regulations to pharmacists, pharmacy technicians and pharmacy
Read moreThe Department of Health and Social Care (DHSC) has today (31/05/2024) confirmed the following list of price concessions for May 2024. This announcement comes late in the month and follows the decision by DHSC, under the direction of Ministers, to impose changes to concessions pricing from April 2024 to try to manage purchase margins. DHSC has
Read moreThe Health and Social Care Select Committee has today published the report of its inquiry into community pharmacy. The Committee noted that community pharmacies are ‘creaking under the strain of funding pressures’, and the MPs warned about the impact medicine supply issues. The Committee also recognised the potential that pharmacies have to expand their clinical
Read moreA new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 9 April 2024) has been published and includes articles on: Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions Letters and medicine recalls sent to healthcare professionals in
Read more
